BIOMAT Database Logo BIOMAT Database Logo

Cytomegalovirus viremia in HIV-infected patients treated with zidovudine. 1990

M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Department of Virology, University Hospital of Montpellier, France.

We followed the course of cytomegalovirus (CMV) viremia in 65 patients treated with zidovudine for symptomatic HIV-1 infection. Blood samples were tested for the presence of CMV before initiation of treatment and every 3 months thereafter. 13 patients (20%) showed a positive CMV viremia at initiation of treatment. After 3 months of therapy, only 2 patients (3%) remained viremic. However, the frequency of CMV viremia increased from the 6th month of treatment and 28 (43%) of our patients showed a persistence of, or conversion to, positive viremia during the course of treatment. CMV viremia was associated with a decline in the patients' clinical state in 79% of the cases. In contrast, among the 37 patients, who remained negative for CMV viremia, 73% did not show a progression of the HIV-associated disease. The results suggest that CMV viremia could be considered as a useful marker for HIV-associated disease and its progression as well as for the efficacy of therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
[Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
January 2004, Journal of clinical epidemiology,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Serum beta 2-M in asymptomatic HIV-infected patients treated with zidovudine.
December 1990, AIDS (London, England),
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study.
March 2000, The Journal of infection,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors.
November 1997, AIDS (London, England),
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
September 1993, Journal of neurology,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
July 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
April 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Low-level Viremia in Treated HIV-1 Infected Patients: Advances and Challenges.
August 2022, Current HIV research,
M Segondy, and N Atoui, and J Reynes, and J P Vendrell, and J Ducos, and P Blanc, and J Mandin
Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine.
October 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
Copied contents to your clipboard!